| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 05/24/2007 | US20070116704 Method for the production of an immunostimulating mucin (muc1) |
| 05/24/2007 | US20070116703 Isolated mammalian membrane proteins; related agents |
| 05/24/2007 | US20070116694 Inhibitor of interaction of granzyme b with golgin-160 |
| 05/24/2007 | US20070116689 LIM mineralization protein splice variants |
| 05/24/2007 | US20070116673 fusion proteins; membrane proteins; cancer, metastasis |
| 05/24/2007 | US20070116672 Treatment of rheumatic diseases |
| 05/24/2007 | US20070116670 providing a medicament for the therapy of YB-1 positive diseases, in particular of tumor diseases; expressing a gene or gene fragment in a tumor cell |
| 05/24/2007 | US20070116669 Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases |
| 05/24/2007 | US20070116668 Lymphotoxin-beta, lymphotoxin-beta Complexes, pharmaceutical preparations and therapeutic uses thereof |
| 05/24/2007 | US20070116644 Detectable labeled cobalamin (adenosylcolbalamin) conjugated with peptidesor amino acid residues linked to a chelate compound (ETDA) including a metal radionuclide;antitumor, anticarcinogenic agents; contrast agent for imaging; diagnosis; nontoxic;bioavailability; detectable at low concentrations |
| 05/24/2007 | CA2630559A1 Modified pore-forming protein toxins and use thereof |
| 05/24/2007 | CA2630348A1 Inducible expression systems |
| 05/24/2007 | CA2630012A1 Targeted fusion proteins for cancer therapy |
| 05/24/2007 | CA2630011A1 Skin repair accelerating therapeutic agent containing desacyl ghrelin and derivatives thereof as active ingredient |
| 05/24/2007 | CA2630006A1 Skin repair accelerating therapeutic agent containing ghrelin and derivatives thereof or substance acting on ghs-r1a as active ingredient |
| 05/24/2007 | CA2629881A1 A compound comprising an autoantigenic peptide and a carrier with a mhc binding motif |
| 05/24/2007 | CA2629821A1 Production of recombinant collagen like proteins |
| 05/24/2007 | CA2629786A1 Human bocavirus and methods of diagnosis and treatment |
| 05/24/2007 | CA2629749A1 Chimeric immunoreceptor useful in treating human cancers |
| 05/24/2007 | CA2629715A1 Anti-alpha2 integrin antibodies and their uses |
| 05/24/2007 | CA2629635A1 Compositions of and methods of using stabilized psma dimers |
| 05/24/2007 | CA2629521A1 Dof (dna binding with one finger) sequences and methods of use |
| 05/24/2007 | CA2629491A1 Compositions and methods for modulating hemostasis |
| 05/24/2007 | CA2629363A1 Emp4 gene |
| 05/24/2007 | CA2629350A1 Use of bacteriocins for promoting plant growth and disease resistance |
| 05/24/2007 | CA2629343A1 Hepatitis c virus variants |
| 05/24/2007 | CA2629095A1 Anti-egfr antibodies |
| 05/24/2007 | CA2628928A1 Hepatocyte growth factor intron fusion proteins |
| 05/24/2007 | CA2628628A1 Rankl antibody-pth/pthrp chimeric molecules |
| 05/24/2007 | CA2627370A1 High activity growth factor mutants |
| 05/24/2007 | CA2626850A1 Glucoamylase variants |
| 05/24/2007 | CA2619455A1 Modulation of angiogenesis by a-beta peptide fragments |
| 05/23/2007 | EP1788394A1 Screening for peptides inhibiting PP1c binding to Bcl-2, BCL-Xl and BCL-W proteins |
| 05/23/2007 | EP1788390A1 Screening method |
| 05/23/2007 | EP1788087A1 Immunogenic detoxified mutant toxins |
| 05/23/2007 | EP1788086A1 Death Domain Containing Receptor 5 |
| 05/23/2007 | EP1788085A1 A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 05/23/2007 | EP1787997A1 MU-1, member of the cytokine receptor family |
| 05/23/2007 | EP1787996A2 Cancer-suppressing agents |
| 05/23/2007 | EP1787995A1 Recombinant mussel byssus protein |
| 05/23/2007 | EP1787994A1 TB vaccine and diagnostic based on antigens from M. tuberculosis cell |
| 05/23/2007 | EP1787656A1 Recombinant live fowlpox virus vectors and their use in pharmaceutical compositions against hepatitis c virus |
| 05/23/2007 | EP1787655A2 Meningococcal vaccine composition |
| 05/23/2007 | EP1787654A1 A method of inducing a CTL response |
| 05/23/2007 | EP1787653A2 Pharmaceutical composition containing polypeptide fragments of serralysins |
| 05/23/2007 | EP1787127A2 Molecular diagnostic method and treatment in dementia with lewy bodies |
| 05/23/2007 | EP1786925A2 Genes and polypeptides relating to breast cancers |
| 05/23/2007 | EP1786917A2 Optimized interferon-beta gene |
| 05/23/2007 | EP1786907A2 Screening assays for inhibitors of a staphylococcus aureus siderophore |
| 05/23/2007 | EP1786897A2 Means and methods for producing a stabilized cell of interest |
| 05/23/2007 | EP1786896A1 Methods for identifying factors for differentiating definitive endoderm |
| 05/23/2007 | EP1786835A2 Antiangiogenic compounds, pharmaceutical composition containing said compounds and the use thereof |
| 05/23/2007 | EP1786834A2 Implantable power sources and sensors |
| 05/23/2007 | EP1786832A1 Transport protein which is used to introduce chemical compounds into nerve cells |
| 05/23/2007 | EP1786829A1 Process for isolating biomaterial from tissue and an isolated biomaterial extract prepared therefrom |
| 05/23/2007 | EP1786465A2 Methods for detecting and treating autoimmune disorders |
| 05/23/2007 | EP1786458A2 Y2/y4 selective receptor agonists for therapeutic interventions |
| 05/23/2007 | EP1786450A2 Hiv immunostimulatory compositions |
| 05/23/2007 | EP1786449A2 Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
| 05/23/2007 | EP1786445A2 Live microbial microbicides |
| 05/23/2007 | EP1730168A4 Functional method for generating or screening for ligands which modulate steroid hormone receptors |
| 05/23/2007 | EP1627049A4 Novel trichoderma genes |
| 05/23/2007 | EP1613752B1 Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis b core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine |
| 05/23/2007 | EP1594446A4 CALCIUM-SENSING RECEPTOR 2 (CaR2) AND METHODS FOR USING |
| 05/23/2007 | EP1519951B1 Cationic linear peptides having antifungal properties |
| 05/23/2007 | EP1307537B1 Neospora caninum isolate |
| 05/23/2007 | EP1265921B1 Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| 05/23/2007 | EP1238275A4 Characterization of hybridized polymer molecules based on monomer-interface interactions |
| 05/23/2007 | EP1144637B1 Wuschel (wus) gene homologs |
| 05/23/2007 | EP1056881B1 A simplified system for generating recombinant adenoviruses |
| 05/23/2007 | EP1029916B1 Human lysophosphatidic acid receptor and use thereof |
| 05/23/2007 | EP1019074B1 Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 05/23/2007 | EP1015015B1 pRb2/p130 PEPTIDE INHIBITORS OF cdk2 KINASE ACTIVITY |
| 05/23/2007 | EP1012274B1 Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l) |
| 05/23/2007 | EP0970203B1 Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease in humans |
| 05/23/2007 | EP0937254B1 Monoclonal antibody directed against MxA and MxB |
| 05/23/2007 | EP0873407B1 Apo-2 ligand |
| 05/23/2007 | EP0820469B1 Identification, purification and uses of leczymes and carbohydrate ligands |
| 05/23/2007 | EP0754223B1 Non-pathogenic strains of hiv-1 |
| 05/23/2007 | CN1969046A Peptide substrates recognisable by a botulinum toxin A, BoNT/A and the use thereof |
| 05/23/2007 | CN1969045A Cell with improved secretion mediated by MrgA protein or homologue |
| 05/23/2007 | CN1968964A Oligomeric peptides and their use for the treatment of HIV infections |
| 05/23/2007 | CN1968963A Peptide-based compounds |
| 05/23/2007 | CN1968962A Novel soluble cd14 antigen |
| 05/23/2007 | CN1968710A Stable peptide mimetic of HIV gp41 fusion intermediate |
| 05/23/2007 | CN1968709A VEGF inhibitors for the treatment of malignant pleural effusion |
| 05/23/2007 | CN1968700A Polymer-based sustained release device |
| 05/23/2007 | CN1968695A Compositions comprising immunomodulatory compounds for the treatment and control of myelodysplastic syndromes and using methods |
| 05/23/2007 | CN1966683A Recombinant adenovirus for expression of novel tumour suppressor gene p53 |
| 05/23/2007 | CN1966528A PEG-W conjugate linked by urea alkyl bond and its preparation method |
| 05/23/2007 | CN1966527A Polyethylene glycol-interferon coupler and its preparation method |
| 05/23/2007 | CN1966524A Novel monoclonal antibody and nematode larval antigens |
| 05/23/2007 | CN1966522A Lignin synthesis related protein and its coding gene and uses |
| 05/23/2007 | CN1966520A Peptides and compounds that bind to a receptor |
| 05/23/2007 | CN1966517A Earthworm protein EP-2 and its separation method and uses |
| 05/23/2007 | CN1966074A Combined vaccine for anthrax and black death |
| 05/23/2007 | CN1317563C Recombined pronucleus expression detection antigen for detecting goose parvovirus anti-body and preparing method |
| 05/23/2007 | CN1317302C 2, 4-dichlorophen artificial antigen, and its preparing method and use |
| 05/23/2007 | CN1317301C Modulation of IL-2-and IL-15-mediated T cell responses |
| 05/23/2007 | CN1317300C Glycine-riched protein and active fragment and use thereof |